MX2022007275A - Composiciones de acidos biliares y compuestos de fenilbutirato. - Google Patents

Composiciones de acidos biliares y compuestos de fenilbutirato.

Info

Publication number
MX2022007275A
MX2022007275A MX2022007275A MX2022007275A MX2022007275A MX 2022007275 A MX2022007275 A MX 2022007275A MX 2022007275 A MX2022007275 A MX 2022007275A MX 2022007275 A MX2022007275 A MX 2022007275A MX 2022007275 A MX2022007275 A MX 2022007275A
Authority
MX
Mexico
Prior art keywords
compositions
phenylbutyrate
compounds
bile acids
methods
Prior art date
Application number
MX2022007275A
Other languages
English (en)
Inventor
Joshua Cohen
Justin Klee
David Wai Fung Ma
Original Assignee
Amylyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylyx Pharmaceuticals Inc filed Critical Amylyx Pharmaceuticals Inc
Publication of MX2022007275A publication Critical patent/MX2022007275A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente divulgación se refiere a composiciones que incluyen un compuesto de fenilbutirato y un ácido biliar, ya métodos para procesar tales composiciones.
MX2022007275A 2019-12-16 2020-12-15 Composiciones de acidos biliares y compuestos de fenilbutirato. MX2022007275A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962948756P 2019-12-16 2019-12-16
US202063030793P 2020-05-27 2020-05-27
US16/940,102 US11583542B2 (en) 2019-12-16 2020-07-27 Compositions of bile acids and phenylbutyrate compounds
PCT/US2020/065145 WO2021126870A1 (en) 2019-12-16 2020-12-15 Compositions of bile acids and phenylbutyrate compounds

Publications (1)

Publication Number Publication Date
MX2022007275A true MX2022007275A (es) 2022-12-13

Family

ID=76316138

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007275A MX2022007275A (es) 2019-12-16 2020-12-15 Composiciones de acidos biliares y compuestos de fenilbutirato.

Country Status (12)

Country Link
US (3) US11583542B2 (es)
EP (1) EP4076426A1 (es)
JP (1) JP2023507152A (es)
KR (1) KR20220128358A (es)
CN (1) CN114929211B (es)
AU (1) AU2020408674A1 (es)
BR (1) BR112022011948A2 (es)
CA (1) CA3161245A1 (es)
IL (1) IL293879A (es)
MX (1) MX2022007275A (es)
TW (1) TW202135791A (es)
WO (1) WO2021126870A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
IL312585A (en) * 2021-11-08 2024-07-01 Amylyx Pharmaceuticals Inc A combination of bile acid and the compound phenyl butyrate for the treatment of neurodegenerative diseases
US12042476B2 (en) 2022-02-04 2024-07-23 Mcmaster University Methods for the treatment of lysosomal storage diseases
WO2024095118A1 (en) 2022-10-31 2024-05-10 Novartis Ag Dosing regimen of a csf-1r inhibitor for use in the treatment of amyotrophic lateral sclerosis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225031A1 (en) 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
WO2004096123A2 (en) 2003-04-02 2004-11-11 Regents Of The University Of Minnesota Methods of promoting cell viability
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
ES2358089T3 (es) 2004-11-01 2011-05-05 Seo Hong Yoo Métodos y composiciones para reducir la neurodegeneración en esclerosis lateral amiotrófica.
AU2005302452B2 (en) 2004-11-01 2010-12-09 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in Amyotrophic Lateral Sclerosis
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
JP2008530100A (ja) 2005-02-10 2008-08-07 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 視覚障害の治療方法
WO2007111992A2 (en) 2006-03-22 2007-10-04 President And Fellows Of Harvard College Methods and compositions for treating hypercholesterolemia and atherosclerosis
US7737175B2 (en) 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
ES2332687B1 (es) 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
CA2720744A1 (en) * 2008-04-09 2009-10-15 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
AU2009246539B2 (en) 2008-05-12 2014-12-04 Children's Medical Center Corporation Methods and compositions for the treatment of obesity
US20110142799A1 (en) 2008-06-23 2011-06-16 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
EP2391370B1 (en) 2009-02-02 2015-06-03 Galmed Research and Development Ltd. Methods and compositions for treating alzheimer's disease
EP2422787A1 (en) 2010-08-17 2012-02-29 Neurotec Pharma, S.L. Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)
WO2013067096A2 (en) 2011-11-01 2013-05-10 Metselex, Inc. Prevention or attenuation of neuropathic pain and kidney injury by tauroursodeoxycholic acid
EP2599477A1 (en) 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
US20150072967A1 (en) 2012-03-20 2015-03-12 Metselex, Inc. Tauroursodeoxycholic acid attentuates or abolishes formation and deposition of amyloid-b peptide
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
DK3016654T3 (en) 2013-07-01 2018-11-05 Bruschettini Srl TAUROURODEOXYCHOLIC ACID (TUDCA) FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS
WO2015073816A1 (en) * 2013-11-14 2015-05-21 Ultragenyx Pharmaceutical Inc. Solid compositions of triglycerides and uses thereof
US20160022684A1 (en) 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
CN107929251A (zh) * 2017-12-26 2018-04-20 兆科药业（广州）有限公司 一种苯丁酸钠片及其制备方法
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds

Also Published As

Publication number Publication date
WO2021126870A1 (en) 2021-06-24
AU2020408674A1 (en) 2022-08-04
CN114929211A (zh) 2022-08-19
US20230210869A1 (en) 2023-07-06
TW202135791A (zh) 2021-10-01
CA3161245A1 (en) 2021-06-24
US11559533B2 (en) 2023-01-24
JP2023507152A (ja) 2023-02-21
EP4076426A1 (en) 2022-10-26
KR20220128358A (ko) 2022-09-20
IL293879A (en) 2022-08-01
US20220117978A1 (en) 2022-04-21
US20210177867A1 (en) 2021-06-17
US11583542B2 (en) 2023-02-21
BR112022011948A2 (pt) 2022-09-06
CN114929211B (zh) 2024-08-20

Similar Documents

Publication Publication Date Title
MX2022007275A (es) Composiciones de acidos biliares y compuestos de fenilbutirato.
MX2019009861A (es) Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas.
EP4364795A3 (en) Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
PH12019502090A1 (en) Herbicidal mixture, composition and method
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
MX2018015302A (es) Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos.
PH12021550028A1 (en) Substituted thiophenecarboxamides and analogues as antibacterials agents
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
EP4327880A3 (en) Solid state form of ribociclib succinate
AU2020258568A8 (en) CD73 inhibitors
AU2017247004A1 (en) Method of treating atherosclerosis
MX2021006126A (es) Proceso de preparacion de una composicion tensioactiva a base de sal de ester de glicina betaina y composicion asi obtenida.
MX2020009840A (es) Granulos que comprenden l-aminoacido y procedimiento de preparacion de los mismos.
WO2021100029A3 (en) Prodrugs of fulvestrant
WO2019004770A3 (ko) 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
NZ732301A (en) Peptide compound, preparation method therefor, and application thereof
WO2018125983A8 (en) Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
GB2547812A (en) Proppant composition and method
MX2020010394A (es) Composicion repelente de insectos que comprende uno o mas acidos grasos repelentes de insectos que tienen entre 9 y 21 atomos de carbono.
MX2018010801A (es) Derivados de acido a-truxilico y composiciones farmaceuticas de los mismos.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
AU2018258588A8 (en) Inhibitors of TRIM33 and methods of use
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
EA202190598A1 (ru) Способ изготовления твердой формы ингибитора бромодомена bet
EP3459933A3 (en) Solid forms of a pharmaceutically active compound